Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen On The Offensive Against Roche’s EPO Mircera; Questions Safety Data

Executive Summary

Amgen is continuing its offensive against Roche's pending EPO product Mircera by signing an exclusive supply contract with a large dialysis provider and criticizing Roche's clinical trial program for the continuous erythropoietin receptor activator

You may also be interested in...



Roche/Amgen EPO Fight Gets Senate Hearing On Patent Defense Rules

The Senate Judiciary Committee is looking at whether to revise an obscure provision in patent law that could affect litigation between Amgen and Roche

Roche/Amgen EPO Fight Gets Senate Hearing On Patent Defense Rules

The Senate Judiciary Committee is looking at whether to revise an obscure provision in patent law that could affect litigation between Amgen and Roche

Mircera EPO Will Benefit From Lower Admin Costs Of Monthly Dosing – Roche

Monthly dosing for Roche's continuous erythropoietin receptor activator Mircera may make it attractive to providers because of the lower costs of administration associated with the extended dosing regimens, according to Pharmaceutical Division CEO William Burns

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel